Literature DB >> 8461467

Complement and virus-specific antibody-dependent infection of normal B lymphocytes by human immunodeficiency virus type 1.

G Gras1, Y Richard, P Roques, R Olivier, D Dormont.   

Abstract

We tested the susceptibility of human purified, normal B lymphocytes to human immunodeficiency virus type 1 (HIV-1) infection, in the presence or absence of complement-sufficient serum and of virus-specific antibodies. Virus replication was detected when cells were infected in the presence of both complement and anti-HIV antibodies (C'-ADE conditions), by day 2 postinfection. Similar results were obtained when B lymphocytes were purified either from peripheral blood (three healthy donors) or from tonsils (four individuals with chronic tonsillitis). HIV infection was shown by polymerase chain reaction (PCR) detection of proviral sequences (gag and pol genes), by p24 antigen synthesis, and by cocultivation assay with MT2 cells. The higher p24 production was obtained when B cells were preactivated for 2 days by phorbol 12-myristate 13-acetate (PMA) before infection and then cultured in the presence of low-molecular weight B-cell growth factor (LMW-BCGF). Expression of virus envelope glycoprotein (gp) 120 could also be detected on a subpopulation of B cells (CD19+, CD22+) by flow cytometry. Blocking experiments with monoclonal antibodies (MoAbs) against CD4, CD21 (complement receptor 2 [CR2]), CD35 (CR1), CD19, and CD5 surface molecules indicated that infection of B cells involves CD4, CD21, and CD35 antigens. Indeed, blocking of CD4 receptor inhibited 10% of p24 production, and blocking of both CD21 and CD35 led to extinction of p24 signal. CR-dependent pathway is thus a major route for C'-ADE of HIV infection in normal B cells. Our results emphasize the importance of studying interactions between HIV and the complement system for better understanding infection mechanisms and the major dysfunctions of B cells in HIV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8461467

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

Review 2.  Enhancing role of complement in HIV infection.

Authors:  A Mouhoub; N Thieblemont; C Delibrias; E Fischer; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

3.  CD40-Mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir.

Authors:  S Moir; R Lapointe; A Malaspina; M Ostrowski; C E Cole; T W Chun; J Adelsberger; M Baseler; P Hwu; A S Fauci
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

4.  Complement opsonization enhances friend virus infection of B cells and thereby amplifies the virus-specific CD8+ T cell response.

Authors:  Custodio Bila; Verena Oberhauser; Christoph G Ammann; Asim Ejaz; Georg Huber; Simone Schimmer; Ron Messer; Marcela Pekna; Dorothee von Laer; Ulf Dittmer; Kim J Hasenkrug; Heribert Stoiber; Zoltán Bánki
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

Review 5.  Influence of dendritic cells on B-cell responses during HIV infection.

Authors:  Johanne Poudrier; Josiane Chagnon-Choquet; Michel Roger
Journal:  Clin Dev Immunol       Date:  2012-02-22

6.  B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells.

Authors:  S Moir; A Malaspina; Y Li; T W Chun; T Lowe; J Adelsberger; M Baseler; L A Ehler; S Liu; R T Davey; J A Mican; A S Fauci
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

7.  EBV renders B cells susceptible to HIV-1 in humanized mice.

Authors:  Donal McHugh; Renier Myburgh; Nicole Caduff; Michael Spohn; Yik Lim Kok; Christian W Keller; Anita Murer; Bithi Chatterjee; Julia Rühl; Christine Engelmann; Obinna Chijioke; Isaak Quast; Mohaned Shilaih; Victoria P Strouvelle; Kathrin Neumann; Thomas Menter; Stephan Dirnhofer; Janice Kp Lam; Kwai F Hui; Simon Bredl; Erika Schlaepfer; Silvia Sorce; Andrea Zbinden; Riccarda Capaul; Jan D Lünemann; Adriano Aguzzi; Alan Ks Chiang; Werner Kempf; Alexandra Trkola; Karin J Metzner; Markus G Manz; Adam Grundhoff; Roberto F Speck; Christian Münz
Journal:  Life Sci Alliance       Date:  2020-06-23

8.  V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

Authors:  Lautaro G Perez; David R Martinez; Allan C deCamp; Abraham Pinter; Phillip W Berman; Donald Francis; Faruk Sinangil; Carter Lee; Kelli Greene; Hongmei Gao; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Robert J O'Connell; Merlin L Robb; Nelson L Michael; Jerome H Kim; Peter Gilbert; David C Montefiori
Journal:  PLoS One       Date:  2017-07-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.